Cefadroxil NDC 68180-182

NDC codes

FDA NDC Directory

Product NDC (as listed)68180-182Labeler and product segments. Claims need a package NDC.

Product NDC at billing width68180-0182Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
68180-182-02	68180018202	75 mL in 1 BOTTLE (68180-182-02)Marketed from Apr 23, 2008
68180-182-03	68180018203	100 mL in 1 BOTTLE (68180-182-03)Marketed from Apr 23, 2008

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Cefadroxil
Generic name (nonproprietary): cefadroxil
Active ingredients: Cefadroxil — 500 mg/5mL
Dosage form: Powder, For suspension
Route: Oral
Labeler: Lupin Pharmaceuticals, Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 065396
Marketing start: Apr 23, 2008
Listing expires: Dec 31, 2026
Other FDA classes: Cephalosporins (Chemical structure)
Identifiers: Product ID 68180-182_3818bd15-cf3a-4b07-bef5-57169a33a170SPL ID 3818bd15-cf3a-4b07-bef5-57169a33a170SPL set ID 27009a05-4d2b-4618-be76-39f348240edaRxCUI 105171, 309048UNII 280111G160
Pharmacologic class: Cephalosporin Antibacterial

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N468180018202 followed by a unit qualifier and the quantity

Package 68180-0182-02. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Oct 8, 2025.

Indications (excerpt from the label)

INDICATIONS AND USAGE Cefadroxil for oral suspension USP is indicated for the treatment of patients with infection caused by susceptible strains of the designated organisms in the following diseases: Urinary tract infections caused by E. coli , P. mirabilis , and Klebsiella species. Skin and skin structure infections caused by staphylococci and/or streptococci. Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes (Group A beta-hemolytic streptococci). Note: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefadroxil monohydrate is generally effective in the eradication of streptococci from the oropha…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 065396

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 065396
Product	Strength	Form · route	Labeler	Product NDC
Cefadroxil	Cefadroxil 250 mg/5mL	Powder, For suspensionOral	Lupin Pharmaceuticals, Inc.	68180-181